Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) effects on perception of illusions, schizotypy and cognition in healthy volunteers
University of Western Australia
36 participants
May 3, 2021
Interventional
Conditions
Summary
The hypothesis is that there are certain types of what are called schizotypy (schizophrenic-like) states or traits that can predict how a person may respond to THC and/or CBD: in a pro- or anti-psychotic manner, to guide potential medicinal use of cannabis in psychiatry. The aim s to compare THC (the psychoactive component in cannabis) with CBD ("non-psychoactive" component in cannabis) on its effects on the multi-sensory perceptions in the healthy volunteers. We have previously shown that certain drugs can produce effects on the perception of illusions that are similar to differences in the perceptions of those illusions by people suffering from schizophrenia. Determining the effect of the cannabinoids on these differences in perceptions in healthy people, and the relationship of those effects with the effect on mild schizophrenic similar states and traits may allow us to determine which people will find THC or CBD to be medicinally helpful, and those that should avoid these drugs.
Eligibility
Inclusion Criteria2
- They are between 18 and 59 years of age.
- They are healthy (have no ongoing medical, including psychiatric, condition, other than acne.
Exclusion Criteria9
- Any current medical (including psychiatric) condition other than acne.
- Women that are pregnant or breast-feeding.
- Women that fertile, sexually active, and not using a contraceptive.
- Using current prescription medications other than contraceptives or acne medications.
- A family history of a psychotic illness (E.g., schizophrenia or bipolar disorder) in their first-degree relatives.
- Use of any drugs other than contraceptives or acne medications 48 hours before the testing days. These include prescription medications, over-the-counter medications or “naturopathy” medications such as St John’s Wort (that can interfere with drug metabolism), but do not include nicotine if the person is nicotine-dependent as withdrawal from nicotine produces an unusual physiological state.
- History of a major brain or head injury.
- Need for a hearing aid.
- Poor eyesight when wearing glasses.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The participants receive each of oral THC 5 mg (twice a day, 2.5 hours apart, one day only ), oral CBD 500 mg (twice a day, 2.5 hours apart, one day only), and placebo (same excipient as in THC and CBD, twice a day, 2.5 hours apart, one day only) each being at least one week apart. Participants will be given 2 oil capsules on all three testing days, one day receiving placebo (capsule of olive oil), THC (capsule of THC in olive oil ), and CBD (capsule of olive oil) so that the duration of the study is one day a week for 3 weeks (~14 days)
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12621000469819